(RTTNews) - India-based Glenmark Pharmaceuticals Inc.'s USA subsidiary, Thursday announced the launch of Clindamycin Phosphate Foam, 1 percent for the treatment of acne. The company added that ...
1 Glenmark's Clindamycin Phosphate Foam, 1% is only approved for the indication(s) listed in Glenmark's approved label. 2 All brand names and trademarks are the property of their respective owners. 3 ...
Nov. 4, 2004 — The U.S. Food and Drug Administration (FDA) has approved clindamycin foam 1% for the topical treatment of acne; a disposable pen-like delivery system for somatropin injection; estradiol ...
Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of clindamycin phosphate foam, 1%. Glenmark’s clindamycin phosphate foam, 1% is bioequivalent and therapeutically equivalent to the ...
Investing.com -- Glenmark Pharmaceuticals (NSE: GLEN) Inc., USA, has announced the launch of Clindamycin Phosphate Foam, 1%, a product that is bioequivalent and therapeutically equivalent to Evoclin® ...
Mumbai (Maharashtra) [India], September 21 (ANI/PR Newswire): Glenmark Pharmaceuticals Ltd. (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for ...
MAHWAH, N.J., Feb. 13, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch 1 of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin Phosphate Foam, 1% is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results